Golidocitinib plus CHOP for new T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have been diagnosed with a type of T-cell lymphoma that is not NK/T-cell lymphoma.
- You have at least one tumor that can be measured on a CT scan (a lymph node >1.5 cm or other tumor >1 cm).
- Your blood counts, liver, kidney, and heart function are good enough for the study.
- You have not had a heart attack, unstable angina, heart failure, or major heart rhythm problems in the last 6 months.
- You do not have lymphoma that has spread to your brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
This study tests an oral pill called golidocitinib (a JAK1 inhibitor) as the first treatment for people newly diagnosed with peripheral T-cell lymphoma. The pill targets a pathway that cancer cells use to grow, and the goal is to shrink tumors or slow the disease.
This study tests a new pill called golidocitinib for people newly diagnosed with certain types of peripheral T-cell lymphoma who have not been treated before. The goal is to see if it is safe and effective in shrinking or controlling the lymphoma.
This trial tests a combination of two drugs, chidamide and golidocitinib, for peripheral T-cell lymphoma that has come back or not responded to earlier treatments. The goal is to see if this combination can help shrink or control the lymphoma.
This Phase 2 trial compares two chemotherapy approaches—adding lenalidomide to CHOP versus CHOP alone—for people with untreated peripheral T-cell lymphoma (PTCL). The goal is to see if the added medicine improves response and safety.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.